Vivos Therapeutics, Inc. - VVOS STOCK NEWS

Vivos Therapeutics (NASDAQ: VVOS) announced the acquisition of patents and product rights from Advanced Facialdontics, enhancing its offerings for treating obstructive sleep apnea (OSA) and related conditions. This includes the Preventive Oral Device (POD^®) for Temporomandibular Joint Dysfunction (TMD) and the Night Block for alleviating traditional treatment downsides. The acquisition broadens Vivos' patent portfolio and aims to open new revenue streams, targeting millions suffering from TMD and Bruxism. CEO Kirk Huntsman emphasized the strategic importance, stating it allows for a complete range of products at competitive prices, enhancing market position.

Vivos Therapeutics (NASDAQ:VVOS) announced that Chairman and CEO Kirk Huntsman will present at the Emerging Growth Conference on February 22, 2023, at 12:35 pm ET. The event invites both institutional and individual investors to participate in a real-time interactive presentation. Vivos focuses on innovative treatments for sleep-disordered breathing, particularly mild-to-moderate obstructive sleep apnea and snoring in adults. The Vivos Method, which has successfully treated around 31,000 patients through trained dentists, offers a noninvasive, nonsurgical solution. The presentation will also be available for replay on Vivos' website for 30 days following the event.

Vivos Therapeutics, Inc. (NASDAQ: VVOS) announced on January 20, 2023, that it has regained compliance with Nasdaq's minimum bid price requirement as per Listing Rule 5550(a)(2). The company previously received a notice on November 3, 2022, for failing to maintain a closing bid price of $1.00 for 30 consecutive business days. By meeting the requirement for a minimum closing bid price of $1.00 for at least 10 consecutive trading days, Vivos is now compliant with all Nasdaq listing standards. The Nasdaq has confirmed that this matter is now closed, marking a significant improvement in Vivos' stock status.

Vivos Therapeutics (NASDAQ: VVOS) has successfully completed a private placement offering, raising $8 million in gross proceeds. After expenses, the company expects net proceeds of approximately $7.4 million to be used for general working capital as it aims to drive revenue growth and control expenses in 2023. The offering included 2 million shares of common stock and warrants for 6.67 million shares at an effective price of $1.20 per share. Vivos promises to file a resale registration statement to allow subsequent trading of these securities.

Vivos Therapeutics (NASDAQ: VVOS) has announced a definitive agreement with an institutional investor to raise approximately $8 million through a private placement at $1.20 per unit. Each unit includes one share of common stock and a warrant exercisable at the same price for five and a half years. After fees and expenses, net proceeds are expected to be $7.5 million. The offering is set to close on January 9, 2023. The securities will not be registered under the Securities Act, and a resale registration statement will be filed within 30 days of closing.

Vivos Therapeutics (NASDAQ: VVOS) announced a significant milestone with the FDA granting clearance for its DNA appliance, marking the first formal recognition of Vivos' proprietary technology for treating mild-to-moderate obstructive sleep apnea (OSA). This 510(k) clearance is Vivos' third FDA approval for its oral devices, enhancing the company's position in the sleep treatment market. Clinical data revealed 28% of patients saw resolution of OSA. The device aims to expand palates and improve airway function, providing a non-invasive alternative to traditional OSA therapies.

Vivos Therapeutics reported its financial results for the second and third quarters of 2022, indicating revenue of $4.2 million in both quarters. The company addressed delays in filing 10-Q reports due to revenue recognition policy reviews, concluding that the impact was minimal. Notably, appliance revenue increased by 28% and 20% in Q2 and Q3 respectively, bolstered by higher sales volumes. However, gross profit decreased, with gross margins at 62% and 59% for Q2 and Q3. Vivos is now current with SEC filings and plans to achieve positive cash flow in the next 12-18 months.

Vivos Therapeutics (NASDAQ: VVOS) will release its second and third quarter 2022 financial results on December 20, 2022, after market close. The company will hold a conference call at 5:00 pm ET to discuss these results and recent company developments. Vivos has faced delays in filing its Form 10-Q due to technical discussions with accountants. With the filing of these results, Vivos aims to become current in its financial filings for Nasdaq compliance. The company specializes in treatments for dentofacial abnormalities and obstructive sleep apnea.

Vivos Therapeutics announces a strategic collaboration with Nexus Dental Systems expected to boost revenues immediately. This partnership combines Vivos’ out-of-network Billing Intelligence Service with Nexus’ in-network platform, enhancing medical billing access for sleep and breathing disorder treatments. The collaboration aims to improve reimbursement rates and reduce out-of-pocket expenses for patients, potentially increasing case acceptance for Vivos-trained dentists. Vivos currently boasts a 98% success rate for reimbursement claims.